RASSF1A methylation, YAP1 activation and metastasis: a new role for an old foe in lung cancer

Min Hee Oh, William W. Lockwood

Abstract

The majority of lung cancer patients die not from primary, but metastatic disease. While mutations/rearrangements in oncogenes such as KRAS, EGFR and ALK, occur early in tumorigenesis, experimental evidence suggests that additional alterations are required to promote tumor invasion and progression (1). Despite knowing a great deal about the molecular pathways associated with the metastatic phenotype, little is known about how these factors become deregulated to drive the spread of lung cancer cells.